![Marcos Milla](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Marcos Milla
Directeur/Membre du Conseil chez
Lumen Bioscience, Inc.
Profil
Marcos Milla currently works at Lumen Bioscience, Inc., as Director, ImmunOs Therapeutics AG, as Director from 2022, Enlaza Therapeutics, Inc., as Director, Alentar Biosciences, Inc., as Director, and Samsara BioCapital LLC, as Venture Partner from 2021.
Dr. Milla also formerly worked at Roche Pharmaceuticals, Inc., as Director from 2005 to 2009, Janssen Pharmaceuticals, Inc., as Senior Director-Discovery Sciences from 2014 to 2016, Adaptive Biotechnologies Corp., as Head-Discovery from 2016 to 2017, and Synthorx, Inc., as Chief Scientific Officer from 2018 to 2020.
Dr. Milla received his undergraduate degree in 1990 from Universidad Peruana Cayetano Heredia and doctorate degree in 1990 from Saint Louis University School of Medicine.
Postes actifs de Marcos Milla
| Sociétés | Poste | Début |
|---|---|---|
Lumen Bioscience, Inc.
 Lumen Bioscience, Inc. BiotechnologyHealth Technology Develops biologic drug platform | Directeur/Membre du Conseil | - |
Enlaza Therapeutics, Inc.
 Enlaza Therapeutics, Inc. BiotechnologyHealth Technology Develops biological drugs and protein therapeutics | Directeur/Membre du Conseil | - |
ImmunOs Therapeutics AG
 ImmunOs Therapeutics AG BiotechnologyHealth Technology Engages in discovering and developing novel human immunomodulatory proteins | Directeur/Membre du Conseil | 07/06/2022 |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara BioCapital invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and pharmaceuticals. It provides early and later stage capital requirements. | Private Equity Investor | 01/04/2021 |
Anciens postes connus de Marcos Milla
| Sociétés | Poste | Fin |
|---|---|---|
| SYNTHORX, INC. | Directeur Technique/Scientifique/R&D | 23/01/2020 |
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Private Equity Investor | 01/07/2017 |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Corporate Officer/Principal | 01/04/2016 |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Directeur/Membre du Conseil | 01/04/2009 |
Formation de Marcos Milla
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
19
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Commercial Services |
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Health Technology |
Universidad Peruana Cayetano Heredia
 Universidad Peruana Cayetano Heredia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Adaptive Biotechnologies Corp.
 Adaptive Biotechnologies Corp. BiotechnologyHealth Technology Develops minimal residual disease and immune medicine | Health Technology |
Synthorx, Inc.
 Synthorx, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that uses synthetic biology to discover and develop protein therapeutics | Health Technology |
Saint Louis University School of Medicine
 Saint Louis University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara BioCapital invests in companies located in the United States. The firm targets companies operating in the fields of biotechnology and pharmaceuticals. It provides early and later stage capital requirements. | Finance |
Lumen Bioscience, Inc.
Lumen Bioscience, Inc. BiotechnologyHealth Technology Develops biologic drug platform | Health Technology |
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG BiotechnologyHealth Technology Engages in discovering and developing novel human immunomodulatory proteins | Health Technology |
Enlaza Therapeutics, Inc.
Enlaza Therapeutics, Inc. BiotechnologyHealth Technology Develops biological drugs and protein therapeutics | Health Technology |
